Table 4.

Comparison of DOTA-NAP-d-Asp-d-Asp and DOTA-Phospho-MSH_2-9 with different analogs of MSH-NAP-amide containing modifications at the C-terminal or N-terminal end or in the N^ε-lysine side chain that yield different overall net charges.

Peptide		N-terminal	C-terminal	Nε-Lys	Net charge	Reference
A	{[Ac-Nle4,Asp5,d-Phe7,Lys11(DOTA)]-α-MSH4-11}-d-Asp-d-Asp-OH	Ac	d-Asp-d-Asp	DOTA	−2
B	[DOTA-Gly2,Tyr(P)3,Nle4,Asp5,d-Phe7]-α-MSH2-9 [DOTA-Phospho-MSH2-9]	DOTA	Trp-amide	–	−1
C	[DOTA-Nle4,Asp5,d-Phe7,Lys11(Suc)]-α-MSH4-11-carboxylate	DOTA	OH	Suc	−1	(14)
D	[DOTA-Nle4,Asp5,d-Phe7,Lys11(Suc)]-α-MSH4-11	DOTA	Amide	Suc	0	(14)
E	[Ac-Nle4,Asp5,d-Phe7,Lys11(DOTA)]-α-MSH4-11-carboxylate	Ac	OH	DOTA	0	(14)
F	[Ac-Nle4,Asp5,d-Phe7,Lys11(DOTA)]-α-MSH4-11 [DOTA-NAP-amide]	Ac	Amide	DOTA	+1	(13)
G	[DOTA-Nle4,Asp5,d-Phe7,Lys11(Ac)]-α-MSH4-11	DOTA	Amide	Ac	+1	(14)
H	[DOTA-Nle4,Asp5,d-Phe7]-α-MSH4-11	DOTA	Amide	H	+2	(14)